A Randomized Phase II Study to Determine the Effect of 2 Different Doses AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 26 Jun 2017
At a glance
- Drugs Aflibercept (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 16 Sep 2016 Status changed from active, no longer recruiting to completed.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 18 Mar 2013 Planned end date changed from 1 Apr 2016 to 1 Oct 2016 as reported by ClinicalTrials.gov.